JPRN-UMIN000033514已完成4 期
Switching test from cinalcalcet to etelcalcetide in secondary hyperpapathyroidism patients ongoing hemodialysis - Switching test from cinalcalcet to etelcalcetide
Fujita Memorial Hospital, Department of Internal Medicine0 个研究点目标入组 52 人开始时间: 2018年8月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
Parathyroid hormone significantly decreased in the change group from cinacalcet to etelcalcetide after 12 months.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with malignant tumors
研究者
相似试验
已完成
4 期
Switching from cinacalcet to ebocalcet in secondary hyperparathyroidism patients during hemodialysis.Secondary hyperparathyroidismJPRN-UMIN000036862Fujita Memorial Hospita, Department of Internal Medicine20
已完成
不适用
Clinical efficacy of intravenous calcium-sensing receptor agonist (etelcalcetide hydrochloride) for secondary hyperparathyroidismEnd-stage renal diseaseJPRN-UMIN000027408Saitama Tsukinomori Clinic32
已完成
不适用
Prescription change from cinacalcet hydrochloride to evocalcet in hemodialysis patientsChronic hemodialysis patients with secondary hyperparathyroidismJPRN-UMIN000036702Kidney Disease and Dialysis Center, Hidaka Hospital, Hidaka-kai147
已完成
1 期
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic RicketsHypophosphatemic Rickets, X-Linked DominantNCT00195936Children's Mercy Hospital Kansas City8
已完成
不适用
The effect of calcimimetics on complications of chronic kidney diseaseJPRN-UMIN000035414Saitama Tsukinomori Clinic32